Cargando…

Tocilizumab is recommended for the treatment of severe COVID-19

Detalles Bibliográficos
Autores principales:	Zhou, Yonggang, Wei, Haiming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540282/ https://www.ncbi.nlm.nih.gov/pubmed/33038768 http://dx.doi.org/10.1016/j.ebiom.2020.103045

Ejemplares similares

Why tocilizumab could be an effective treatment for severe COVID-19?
por: Fu, Binqing, et al.
Publicado: (2020)

Effective treatment of severe COVID-19 patients with tocilizumab
por: Xu, Xiaoling, et al.
Publicado: (2020)

Tocilizumab in severe COVID-19: A promise fulfilled
por: Levi, Marcel
Publicado: (2022)

Tocilizumab for severe COVID-19: A promising intervention affecting inflammation and coagulation
por: Levi, Marcel
Publicado: (2020)

Testing the efficacy of tocilizumab in patients with COVID-19 pneumonia
por: Agirbasli, Mehmet, et al.
Publicado: (2021)

Tocilizumab, an Exploratory Treatment for Severe COVID-19 Patients
por: Wang, Yong, et al.
Publicado: (2022)

Tocilizumab for treatment patients with COVID-19: Recommended medication for novel disease
por: Samaee, Hamidreza, et al.
Publicado: (2020)

Tocilizumab in severe COVID-19
por: Lucio Liberato, Nicola, et al.
Publicado: (2020)

Efficacy of the early treatment with tocilizumab-hydroxychloroquine and tocilizumab-remdesivir in severe COVID-19 Patients
por: Sarhan, Rania M., et al.
Publicado: (2022)

Efficacy of tocilizumab treatment in severely ill COVID-19 patients
por: Zhao, Jie, et al.
Publicado: (2020)

Tocilizumab for severe COVID-19 pneumonia
por: Mourad, Jean-Jacques, et al.
Publicado: (2020)

Tocilizumab for severe COVID-19 pneumonia
por: Lipworth, Brian J, et al.
Publicado: (2020)

Tocilizumab for severe COVID-19 pneumonia
por: Piano, Salvatore, et al.
Publicado: (2020)

Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial
por: Wang, Dongsheng, et al.
Publicado: (2021)

Tocilizumab versus the Covid19 tempest: All’s well that ends well or much ado about nothing?
por: Lee, Todd C., et al.
Publicado: (2021)

Predictors of the Outcomes Following the Tocilizumab Treatment for Severe COVID-19
por: Singla, Karan, et al.
Publicado: (2022)

Tocilizumab, Adipokines and Severe Complications of COVID-19
por: Fioravanti, Antonella, et al.
Publicado: (2020)

Clinical efficacy of tocilizumab treatment in severe and critical COVID-19 patients
por: Zeng, Jia, et al.
Publicado: (2020)

Effective treatment of severe acute pancreatitis and COVID-19 pneumonia with tocilizumab
por: Zielecki, Piotr, et al.
Publicado: (2020)

Successful treatment of severe COVID-19 pneumonia and hyperinflammatory syndrome with tocilizumab
por: Gentile, Giorgio, et al.
Publicado: (2021)

Experience of using tocilizumab for treatment in Indonesian patients with severe COVID-19
por: Widysanto, Allen, et al.
Publicado: (2021)

Real-Life Use of Tocilizumab in the Treatment of Severe COVID-19 Pneumonia
por: Alex, Ruth, et al.
Publicado: (2022)

Impact of tocilizumab administration on mortality in severe COVID-19
por: Tsai, Andrew, et al.
Publicado: (2020)

Tocilizumab for severe COVID-19 pneumonia – Authors' reply
por: Guaraldi, Giovanni, et al.
Publicado: (2020)

Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia
por: Rosas, Ivan O., et al.
Publicado: (2021)

Predictors of Mortality in Tocilizumab-Treated Severe COVID-19
por: Pagkratis, Konstantinos, et al.
Publicado: (2022)

Universal masking for COVID-19: evidence, ethics and recommendations
por: Chan, Tak Kwong
Publicado: (2020)

Complex Pathophysiological Mechanisms and the Propose of the Three-Dimensional Schedule For Future COVID-19 Treatment
por: Zhou, Yonggang, et al.
Publicado: (2021)

Preliminary recommendations for lung surgery during COVID‐19 epidemic period
por: Li, Xin, et al.
Publicado: (2020)

Tocilizumab for treatment of patients with severe COVID–19: A retrospective cohort study
por: Kewan, Tariq, et al.
Publicado: (2020)

Comparing efficacy and safety of tocilizumab and methylprednisolone in the treatment of patients with severe COVID-19
por: Abbasian, Ladan, et al.
Publicado: (2022)

Severity-Adjusted Dexamethasone Dosing and Tocilizumab Combination for Severe COVID-19
por: Hong, Jin Yeong, et al.
Publicado: (2022)

United States Cutaneous Lymphoma Consortium recommendations for treatment of cutaneous lymphomas during the COVID-19 pandemic
por: Zic, John A., et al.
Publicado: (2020)

The Third Wave of the COVID-19 in Afghanistan: An Update on Challenges and Recommendations
por: Nemat, Arash, et al.
Publicado: (2021)

Tocilizumab and COVID-19
por: Chaudhry, Dhruva, et al.
Publicado: (2020)

Mesenchymal stem cells in the treatment of severe COVID-19
por: Kesari, Santosh, et al.
Publicado: (2021)

Tocilizumab for treatment of mechanically ventilated patients with COVID-19
por: Somers, Emily C, et al.
Publicado: (2020)

Tocilizumab for Treatment of Mechanically Ventilated Patients With COVID-19
por: Somers, Emily C, et al.
Publicado: (2020)

Authors’ Reply to: Tocilizumab, Adipokines and Severe Complications of COVID-19
por: Liu, Bin, et al.
Publicado: (2020)

Tocilizumab in HIV patient with severe COVID-19: case report
por: Bertozzi, Pedro Vieira, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jgdvada9f412q6lmed5fde9bar